A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGβ conjugate

Breast Cancer Research and Treatment

Volumn 79, Issue 1, 2003, Pages 1-10

  Bodek, Gabriel ^a   Rahman, Nafis Ahmed ^b   Zaleska, Monika ^a   Soliymani, Rabah ^c   Lankinen, Hikka ^c   Hansel, William ^d   Huhtaniemi, Ilpo ^b   Ziecik, Adam J ^a  

^a INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Breast cancer; Hecate CG ; LH receptor

Indexed keywords

ESTROGEN; LACTATE DEHYDROGENASE; LUTEINIZING HORMONE RECEPTOR; PEPTIDE DERIVATIVE; PHENYLALANYLALANYLLEUCYLALANYLLEUCYLLYSYLALANYLLEUCYLLYSYLLYSYLALANYLLEUCYL LYSYLLYSYLLEUCYLLYSYLLYSYLALANYLLEUCYLLYSYLLYSYLALANYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME RELEASE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEYDIG CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CARCINOMA; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; L-LACTATE DEHYDROGENASE; LEYDIG CELL TUMOR; MALE; MELITTEN; MICE; PEPTIDE FRAGMENTS; RECEPTORS, LH; RECOMBINANT FUSION PROTEINS; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0038076002     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023351819956     Document Type: Article

References (37)

1. McPherson K, Steel CM, Dixon JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 9: 624-628, 2000
2. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocr Rev 11: 221-265, 1990
3. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746, 1996
4. Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med 7: 548-552, 2001
5. Magrath T: Targeted approaches to cancer therapy. Int J Cancer 56: 163-166, 1994
6. Pierce JG, Parsons TF: Glycoprotein hormones: structure and function. Annu Rev Biochem 50: 466-495, 1981
7. Ziecik AJ, Stanchev PD, Tilton JE: Evidence for the presence of luteinizing hormone/human chorionic gonadotropin-binding sites in the porcine uterus. Endocrinology 119: 1159-1163, 1986
8. Rao CV: The beginning of a new era in reproductive biology and medicine: expression of low levels of functional luteinizing hormone/human chorionic gonadotropin receptors in nongonadal tissue. J Physiol Pharmacol 47: 41-53, 1996
9. Lojun S, Bao S, Lei ZM, Rao CV: Presence of functional luteinizing hormone/chorionic gonadotropin (CG) receptors in human breast cell lines: implications supporting the premise that CG protects women against breast cancer. Biol Reprod 57: 1202-1210, 1997
10. Meduri G, Charnaux N, Loosfelt H, Jolivet A, Spyratos F, Brailly S, Milgrom E: Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res 1: 857-864, 1997
11. Tao YX, Lei ZM, Rao CV: The presence of luteinizing hormone/human chorionic gonadotropin receptors in lactating rat mammary glands. Life Sci 60: 1297-1303, 1997
12. Alvarado MV, Alvarado NE, Russo J, Russo IH: Human chorionic gonadotropin inhibits proliferation and induces expression of inhibin in human breast epithelial cells in vitro. In Vitro Cell Dev Biol Anim 30: 4-8, 1994
13. Russo IH, Koszalka M, Russo J: Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst 1: 1286-1289, 1990
14. Russo IH, Koszalka M, Russo J: Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Br J Cancer 64: 481-484, 1991
15. Ehrlich P: The relationship existing between chemical constitution, distribution, and pharmacological action. In: Himmelweite F, Marquardt M, Dale H (eds) The Collected Papers of Paul Ehrlich. Vol. 1, Pergamon, Elmsford, New York: 1956, pp 596-618
16. Hertler AA, Frankel AE: Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1932-1942, 1989
17. Pastan I, FitzGerald D: Recombinant toxins for cancer treatment. Science 22: 1173-1177, 1991
18. FitzGerald D, Pastan I: Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 4: 1455-1463, 1989
19. Singh V, Sairam MR, Bhargavi GN, Akhras RG: Hormonotoxins. Preparation and characterization of ovine luteinizing hormone-gelordn conjugate. J Biol Chem 25: 3089-3095, 1989
20. Boman HG: Antibacterial peptides: key components needed in immunity. Cell 65: 205-207, 1991
21. Zasloff M: Antibiotic peptides as mediators of innate immunity. Curr Opin Immunol 4: 3-7, 1992
22. Lee JY, Boman A, Sun CX, Andersson M, Jornvall H, Mutt V, Boman HG: Antibacterial peptides from pig intestine: isolation of a mammalian cecropin. Proc Natl Acad Sci USA 86: 9159-9162, 1989
23. Dempsey CE: The actions of melittin on membranes. Biochim Biophys Acta 7: 143-161, 1990
24. Weaver AJ, Kemple MD, Brauner JW, Mendelsohn R, Prendergast FG: Fluorescence, CD, attenuated total reflectance (ATR) FTIR, and 13C NMR characterization of the structure and dynamics of synthetic melittin and melittin analogues in lipid environments. Biochemistry 11: 1301-1313, 1992
25. Tosteson MT, Alvarez O, Hubbell W, Bieganski RM, Attenbach C, Caporales LH, Levy JJ, Nutt RF, Rosenblatt M, Tosteson DC: Primary structure of peptides and ion channels. Role of amino acid side chains in voltage gating of melittin channels. Biophys J 58: 1367-1375, 1990
26. Henk WG, Todd WJ, Enright FM, Mitchell PS: The morphological effects of two antimicrobial peptides, hecate-1 and melittin on Escherichia coli. Scanning Microsc 9: 501-507, 1995
27. Morbeck DE, Roche PC, Keutmann HT, McCormick DJ: A receptor binding site identified in the region 81-95 of the beta-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (CG). Mol Cell Endocrinol 97: 173-181, 1993
28. Leuschner C, Enright FM, Melrose PA, Hansel W: Targeted destruction of androgen-sensitive and - insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 46: 116-125, 2001
29. Kananen K, Markkula M, El-Hefnawy T, Zhang FP, Paukku T, Su JG, Hsueh AJ, Huhtaniemi I: The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice. Mol Cell Endocrinol 119: 135-146, 1996
30. Lowry OH, Rosebrough NJ, Faar AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275: 1951
31. Ferguson KM, Hayes MM, Jeffcoate SL: In: Hunter WM, Corrie JE (eds) Preparation of tracer LH and FSH for multicenter use, Immunoassays for Clinical Chemistry, Churchil-Livingstone, Edinburgh, 1983, pp 289-294
32. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 16: 1371-1388, 1998
33. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 3: 1829-1846, 1999
34. Russo IH, Koszalka M, Gimotty PA, Russo J: Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis. Br J Cancer 62: 243-247, 1990
35. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG, Yuasa S: Age at first birth and breast cancer risk. Bull World Health Organ 43: 209-221, 1970
36. Kelsey JL, Gammon MD: Epidemiology of breast cancer. Epidemiol Rev 12: 228-240, 1990
37. Bigsby RM, Caperell-Grant A, Madhukar BV: Xenobiotics released from fat during fasting produce estrogenic effects in ovariectomized mice. Cancer Res 1: 865-869, 1997